While PUM1 is downregulated during MASLD progression, upregulation of PUM1 improves lipid deposition, reduces hepatocyte lipotoxic death and inhibits TPM4 expression to reduce HSC activation. Here, PUM1 is linked to metabolic dysfunction-associated steatotic liver disease.